Abstract
Introduction
Premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) have complex treatment needs and may receive sequential combinations of endocrine therapy (ET) or chemotherapy. This study describes healthcare utilization (HRU) and costs among premenopausal women with HR+/HER2- mBC in real-world settings from a payer’s perspective.
Methods
In this retrospective cohort study, premenopausal women with HR+/HER2- mBC who received ET or chemotherapy were identified from the Truven Health Analytics MarketScan database (1 January 2006–31 December 2015). The main HRU outcomes per patient per 6 months (PPP6 M) were measured during each line of therapy and included number of days in inpatient (IP) and outpatient (OP) services. Healthcare costs per patient per month (PPPM) included medical and pharmacy costs.
Results
A total of 3203 patients received first-line, 2194 received second-line, and 1242 received third-line therapy for mBC. Mean number of IP days PPP6 M were 1.6, 1.3, and 1.5 days in the first, second, and third lines, respectively. Mean number of days with OP services PPP6 M was 31.4, 30.9, and 23.3 in the first, second, and third lines, respectively. Among patients receiving ET, mean total healthcare costs were $6521, $4440, and $4555 PPPM in the first, second, and third line, respectively. Among patients receiving chemotherapy, mean total healthcare costs were $16,842, $12,868, and $16,129 PPPM in the first, second, and third line, respectively. These costs were mainly driven by treatment and OP costs.
Conclusion
Real-world HRU and costs among premenopausal women with HR+/HER2- mBC are extensive. Patients who received chemotherapy incurred approximately twice the costs of patients treated with ET.
Funding
Novartis Pharmaceutical Corp.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus. 2014;3:535.
Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7.
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast Cancer Survival. J Clin Oncol. 2016;34(27):3308–14.
Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094–101.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines). Breast Cancer. Version 1.2017 2017. [November 3, 2017].
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069–103.
Andre F, Neven P, Marinsek N, Zhang J, Baladi JF, Degun R, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin. 2014;30(6):1007–16.
Burton T, Byfield SD, Smith GL, Zanotti G, Bell TJ, Perkins JJ, et al. Clinical and economic outcomes by first-line treatment among women with HR +/HER2- metastatic breast cancer in a large US health plan database. Curr Med Res Opin. 2016;32(8):1417–23.
US Food and Drug Administration (FDA), 2017. Abemaciclib Label Information. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 22 Feb 2018.
US Food and Drug Administration (FDA), 2018. Palbociclib Label Information. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 22 Feb 2018.
US Food and Drug Administration (FDA), 2017. Ribociclib Label Information. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 22 Feb 2018].
Guerin A, Dalal AA, Gagnon-Sanschagrin P, Burne R, Gauthier G, Small T, Niravath P. Treatment and monitoring patterns among premenopausal women with HR+/HER2– metastatic breast cancer. Poster session presented at the national comprehensive cancer network 23rd annual conference, Orlando, Fl; 2018.
Jerusalem G, Neven P, Marinsek N, Zhang J, Degun R, Benelli G, et al. Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer. 2015;15:787.
Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012;134(2):815–22.
Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, et al. Palbociclib Combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017;22(9):1028–38.
Tripathy D, Sohn J, Im S-A, Franke F, Bardia A, Harbeck N, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. San Antionio Breast Cancer Symposium; San Antonio2017.
Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33(19):2190–6.
Acknowledgements
Funding
Sponsorship for this study (including article processing charges) was funded by Novartis Pharmaceuticals Corp.
Medical Writing, Editorial, and other Assistance
Medical writing assistance was provided by Sara Kaffashian, an employee of Analysis Group, Inc. Analysis Group received consulting fees from Novartis for the conduct of this study.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contributions
The study sponsor was involved in all stages of the study research and manuscript preparation. All authors participated in the design and analytical approach of the study and contributed to the manuscript development. Results were summarized and interpreted in collaboration with all authors. The manuscript was prepared by the authors with assistance from a professional medical writer ultimately paid by the sponsor. Concept and design (GG, PG-S, AG, RB, TS, PN, AAD); acquisition of data (GG, PG-S, AG, RB, AAD); statistical analysis (GG, PG-S, AG, RB); interpretation of data (GG, PG-S, AG, RB, TS, PN, AAD); drafting of the manuscript (GG, PG-S, AG, RB); critical revision of the manuscript for important intellectual content (GG, PG-S, AG, RB, TS, PN, AAD).
Disclosures
Anand A. Dalal is an employee of Novartis Pharmaceuticals Corp. and may own stock/stock options. Tania Small is an employee of Novartis Pharmaceuticals Corp. and may own stock/stock options. Geneviève Gauthier is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corp. Patrick Gagnon-Sanschagrin is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corp. Annie Guérin is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corp. Rebecca Burne is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corp. Polly Niravath received honoraria from Novartis as a consultant.
Compliance with Ethics Guidelines
Data are de-identified and comply with the Health Insurance Portability and Accountability Act and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards and thus do not require ethics board review and approval.
Data Availability
The claims database (Truven MarketScan Commercial Database) is proprietary, provided by a third-party vendor, and the authors do not have permission to disseminate the data without the vendor's approval. Any researchers interested in obtaining the data for this study can access the data directly through Truven Health Analytics, Inc., under a license agreement, including the payment of appropriate license fees. Researchers can contact Truven at https://marketscan.truvenhealth.com/marketscanportal/.
Author information
Authors and Affiliations
Corresponding author
Additional information
Enhanced content
To view enhanced content for this article go to https://doi.org/10.6084/m9.figshare.5952466.
Rights and permissions
About this article
Cite this article
Gauthier, G., Gagnon-Sanschagrin, P., Guérin, A. et al. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. Adv Ther 35, 503–514 (2018). https://doi.org/10.1007/s12325-018-0689-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-018-0689-x